Hong-Lin He1,2, Ying-En Lee3, Peir-In Liang4, Sung-Wei Lee5, Tzu-Ju Chen6, Ti-Chun Chan6, Chung-Hsi Hsing7, I-Wei Chang1, Yow-Ling Shiue2, Chien-Feng Li6,8,9,10. 1. Department of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan. 2. Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan. 3. Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital & Chang Gung University College of Medicine, Kaohsiung, Taiwan. 4. Department of Pathology, Kaohsiung Medical University Hospital, & Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5. Department of Radiation Oncology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan. 6. Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan. 7. Department of Anesthesiology, Chi-Mei Medical Center, Tainan, Taiwan. 8. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. 9. Department of Biotechnology, Southern Taiwan University of Science & Technology, Tainan, Taiwan. 10. Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Abstract
PURPOSE: Analysis of the nasopharyngeal carcinoma public transcriptome revealed JAK2 was significantly upregulated in tumors, which encouraged us to investigate its prognostic significance and mutational status. MATERIALS & METHODS: We assessed the immune-expression of JAK2 and its relationships with various clinicopathological parameters. JAK2 mutation was detected by PCR followed by sequencing. RESULTS: High expression of JAK2 was significantly associated with advanced tumor staging (p = 0.019). JAK2 overexpression acted as an independent predictor for worse disease-specific survival (p = 0.005), distant metastasis-free survival (p = 0.036), local recurrence-free survival (p = 0.012) and overall survival (p = 0.007). JAK2 mutation was not detected in selected cases with JAK2 protein overexpression. CONCLUSION: JAK2 can serve as a valuable negative prognostic factor and a potential therapeutic target.
PURPOSE: Analysis of the nasopharyngeal carcinoma public transcriptome revealed JAK2 was significantly upregulated in tumors, which encouraged us to investigate its prognostic significance and mutational status. MATERIALS & METHODS: We assessed the immune-expression of JAK2 and its relationships with various clinicopathological parameters. JAK2 mutation was detected by PCR followed by sequencing. RESULTS: High expression of JAK2 was significantly associated with advanced tumor staging (p = 0.019). JAK2 overexpression acted as an independent predictor for worse disease-specific survival (p = 0.005), distant metastasis-free survival (p = 0.036), local recurrence-free survival (p = 0.012) and overall survival (p = 0.007). JAK2 mutation was not detected in selected cases with JAK2 protein overexpression. CONCLUSION:JAK2 can serve as a valuable negative prognostic factor and a potential therapeutic target.